{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T09:02:40Z","timestamp":1781168560226,"version":"3.54.1"},"reference-count":246,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12TR004416"],"award-info":[{"award-number":["K12TR004416"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01TR003715"],"award-info":[{"award-number":["U01TR003715"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.addr.2025.115736","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:17:55Z","timestamp":1763655475000},"page":"115736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Informing development of brain cancer therapies within \"preclinical trials\" using ex vivo patient tumors"],"prefix":"10.1016","volume":"228","author":[{"given":"Adebimpe","family":"Adefolaju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Kram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breanna","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Hingtgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Satterlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2025.115736_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107533","article-title":"Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine","volume":"190","author":"Taverna","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb0015","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.addr.2025.115736_bb0020","article-title":"Patient-derived tumor organoids to model drug response in gastric cancer","volume":"5","author":"Monreal","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0025","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115736_bb0030","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.stem.2025.01.002","article-title":"Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy","volume":"32","author":"Peng","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115736_bb0035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","article-title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","volume":"32","author":"Logun","year":"2025","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115736_bb0045","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noad149","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2016-2020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0050","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.addr.2025.115736_bb0055","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/neuonc\/noz138","article-title":"Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma","volume":"21","author":"Satterlee","year":"2019","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","article-title":"The Need for New Approaches in CNS Drug Discovery: Why Drugs Have Failed, and What Can Be Done to Improve Outcomes","volume":"120","author":"Gribkoff","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.addr.2025.115736_bb0070","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2025.115736_bb0080","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00213-021-05838-3","article-title":"Challenges in CNS drug development and the role of imaging","volume":"238","author":"Howes","year":"2021","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.addr.2025.115736_bb0085","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/d41586-024-00753-x","article-title":"How AI is being used to accelerate clinical trials","volume":"627","author":"Hutson","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115736_bb0090","first-page":"22","article-title":"Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling","volume":"10","author":"Zhang","year":"2023","journal-title":"Mil. Med. Res."},{"key":"10.1016\/j.addr.2025.115736_bb0095","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/neuonc\/noab162","article-title":"Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin\u2014a novel tumor checkpoint controller targeting microtubules","volume":"24","author":"Burgenske","year":"2022","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0100","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s11192-020-03774-1","article-title":"Applying advanced technologies to improve clinical trials: a systematic mapping study","volume":"126","author":"Ngayua","year":"2021","journal-title":"Scientometrics"},{"key":"10.1016\/j.addr.2025.115736_bb0105","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12885-023-11043-6","article-title":"Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map","volume":"23","author":"Fu","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb0110","series-title":"Breast Cancer, in: StatPearls","author":"Menon","year":"2025"},{"key":"10.1016\/j.addr.2025.115736_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1184472","article-title":"A review of FDA approved drugs and their formulations for the treatment of breast cancer","volume":"14","author":"Chaurasia","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.addr.2025.115736_bb0135","first-page":"26","article-title":"Updates of Prostate Cancer from the 2022 World Health Organization Classification of the Urinary and Male Genital Tumors","volume":"3","author":"Guo","year":"2023","journal-title":"J. Clin. Transl. Pathol."},{"key":"10.1016\/j.addr.2025.115736_bb0150","first-page":"33","article-title":"Clinical development of the GnRH agonist leuprolide acetate depot","volume":"4","author":"Chwalisz","year":"2022","journal-title":"FS Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0160","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1053\/j.seminoncol.2022.03.003","article-title":"Novel targeted therapies for advanced non-small lung cancer","volume":"49","author":"Abughanimeh","year":"2022","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0185","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.4682","article-title":"Incidence of Pancreas and Colorectal Adenocarcinoma in the US","volume":"8","author":"Bussetty","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.addr.2025.115736_bb0210","first-page":"63","article-title":"Epidemiology of Melanoma","volume":"9","author":"Saginala","year":"2021","journal-title":"Med. Sci. Basel Switz."},{"issue":"40","key":"10.1016\/j.addr.2025.115736_bb0225","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?","volume":"1990","author":"Eggermont","year":"2004","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.addr.2025.115736_bb0235","series-title":"Bladder Cancer, in: StatPearls","author":"Leslie","year":"2025"},{"key":"10.1016\/j.addr.2025.115736_bb0250","first-page":"133","article-title":"Development of Systemic and Topical Drugs to Treat Non-muscle Invasive Bladder Cancer, Bladder","volume":"1","author":"Jarow","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb0260","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40164-025-00684-x","article-title":"Global burden and trends of hematologic malignancies based on Global Cancer Observatory 2022 and Global Burden of Disease 2021","volume":"14","author":"Pan","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0275","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1634\/theoncologist.2011-0431","article-title":"Accumulating Evidence for a Drug\u2013Drug Interaction Between Methotrexate and Proton Pump Inhibitors","volume":"17","author":"Bezabeh","year":"2012","journal-title":"The Oncologist"},{"key":"10.1016\/j.addr.2025.115736_bb0285","series-title":"Renal Cancer, in: StatPearls","author":"Pandey","year":"2025"},{"key":"10.1016\/j.addr.2025.115736_bb0300","first-page":"561","article-title":"The High-Dose Aldesleukin \u201cSelect\u201d Trial: A Trial to Prospectively Validate Predictive Models of Response Treatment in Patients with Metastatic Renal Cell Carcinoma, Clin. Cancer Res. Off. J. Am. Assoc","volume":"21","author":"McDermott","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0305","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1158\/1078-0432.CCR-24-1199","article-title":"FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma","volume":"30","author":"Fallah","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70224","article-title":"Trend analysis of hematological tumors in adolescents and young adults from 1990 to 2019 and predictive trends from 2020 to 2044: A Global Burden of Disease study","volume":"13","author":"Huang","year":"2024","journal-title":"Cancer Med."},{"key":"10.1016\/j.addr.2025.115736_bb0335","doi-asserted-by":"crossref","DOI":"10.5306\/wjco.v16.i6.105601","article-title":"Updates in the diagnosis and management of ductal adenocarcinoma of the pancreas","volume":"16","author":"Pavlidis","year":"2025","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0355","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb0375","doi-asserted-by":"crossref","unstructured":"M. Price, C. Ballard, J. Benedetti, C. Neff, G. Cioffi, K.A. Waite, C. Kruchko, J.S. Barnholtz-Sloan, Q.T. Ostrom, CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2017\u20132021, Neuro-Oncol. 26 (2024) vi1\u2013vi85. doi:10.1093\/neuonc\/noae145.","DOI":"10.1093\/neuonc\/noae145"},{"key":"10.1016\/j.addr.2025.115736_bb0380","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/biomedicines9030324","article-title":"Current FDA-Approved Therapies for High-Grade Malignant Gliomas","volume":"9","author":"Fisher","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.addr.2025.115736_bb0390","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA Drug Approval Summary: Bevacizumab (Avastin\u00ae) as Treatment of Recurrent Glioblastoma Multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"The Oncologist"},{"key":"10.1016\/j.addr.2025.115736_bb0395","series-title":"Drugs Methodol. Compend","first-page":"149","article-title":"Preclinical In Vivo Drug Development Studies: Limitations, Model Organisms, and Techniques","author":"Negi","year":"2023"},{"key":"10.1016\/j.addr.2025.115736_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fddsv.2024.1355044","article-title":"The (misleading) role of animal models in drug development","volume":"4","author":"Hartung","year":"2024","journal-title":"Front. Drug Discov."},{"key":"10.1016\/j.addr.2025.115736_bb0405","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115736_bb0415","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1046\/j.0305-1846.2000.00288.x","article-title":"Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model","volume":"26","author":"Wharton","year":"2000","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.addr.2025.115736_bb0420","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/neuonc\/nor115","article-title":"Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target","volume":"13","author":"Smith","year":"2011","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0425","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11060-015-1966-z","article-title":"A randomized phase I\/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study","volume":"126","author":"Robins","year":"2016","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.addr.2025.115736_bb0430","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/neuonc\/nou103","article-title":"A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report","volume":"16","author":"Su","year":"2014","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0435","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","article-title":"A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study","volume":"22","author":"Baxter","year":"2020","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0440","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jamaoncol.2024.4361","article-title":"Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial","volume":"10","author":"Sarkaria","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0445","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/neuonc\/noae247","article-title":"Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children\u2019s Oncology Group study","volume":"27","author":"Karajannis","year":"2025","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0450","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood.2024024968","article-title":"Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial","volume":"145","author":"Kyt\u00f6l\u00e4","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.addr.2025.115736_bb0455","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115736_bb0460","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115736_bb0465","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.1038\/s41598-019-47578-7","article-title":"Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer","volume":"9","author":"Shuford","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0470","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41698-022-00335-y","article-title":"Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM","volume":"6","author":"Peterziel","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0475","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/0008-5472.CAN-22-3702","article-title":"High-Throughput Drug Screening of Primary Tumor Cells Identifies Therapeutic Strategies for Treating Children with High-Risk Cancer","volume":"83","author":"Mayoh","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0480","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2022.32","article-title":"Precision oncology using ex vivo technology: a step towards individualised cancer care?","volume":"24","author":"Williams","year":"2022","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0485","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.addr.2025.115736_bb0490","doi-asserted-by":"crossref","first-page":"18911","DOI":"10.1038\/s41598-019-54849-w","article-title":"Improving the odds of drug development success through human genomics: modelling study","volume":"9","author":"Hingorani","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0495","first-page":"1211","article-title":"Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor, Cell","volume":"30","author":"Bhattacharjee","year":"2023","journal-title":"Chem. Biol."},{"key":"10.1016\/j.addr.2025.115736_bb0500","unstructured":"VORASIDENIB FDA label, (2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218784s000lbl.pdf."},{"key":"10.1016\/j.addr.2025.115736_bb0510","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/oncolo\/oyae119","article-title":"Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G","volume":"29","author":"Nelson","year":"2024","journal-title":"The Oncologist"},{"key":"10.1016\/j.addr.2025.115736_bb0515","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1093\/oncolo\/oyae096","article-title":"Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial","volume":"29","author":"Glade Bender","year":"2024","journal-title":"The Oncologist"},{"key":"10.1016\/j.addr.2025.115736_bb0520","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/jnci\/djad085","article-title":"Tazemetostat for tumors harboring SMARCB1\/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C","volume":"115","author":"Chi","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.addr.2025.115736_bb0525","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.21.02840","article-title":"Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial","volume":"40","author":"Eckstein","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0530","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1158\/1078-0432.CCR-23-0983","article-title":"Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial, Clin. Cancer Res","volume":"30","author":"Zhou","year":"2024","journal-title":"Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0535","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0540","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s10143-024-02873-4","article-title":"Transforming brain cancer therapeutics: unlocking the power of blood-brain barrier-targeting strategies for superior treatment outcomes and precision medicine","volume":"47","author":"Viswanathan","year":"2024","journal-title":"Neurosurg. Rev."},{"key":"10.1016\/j.addr.2025.115736_bb0545","first-page":"21","article-title":"Neuroimaging Correlates of Patient-Reported Outcomes in Multiple Sclerosis","volume":"13","author":"Jakimovski","year":"2023","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"10.1016\/j.addr.2025.115736_bb0550","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11136-011-9958-8","article-title":"Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing","volume":"21","author":"Gershon","year":"2012","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.addr.2025.115736_bb0555","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/d41573-021-00190-9","article-title":"Clinical development times for innovative drugs","volume":"21","author":"Brown","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2025.115736_bb0560","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/nrd4793","article-title":"Two decades of new drug development for central nervous system disorders","volume":"14","author":"Kesselheim","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2025.115736_bb0565","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1056\/NEJMra1510061","article-title":"Adaptive Designs for Clinical Trials","volume":"375","author":"Bhatt","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0575","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3390\/jpm12050673","article-title":"The Promise of Nanotechnology in Personalized Medicine","volume":"12","author":"Alghamdi","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0580","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41698-024-00674-y","article-title":"Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors","volume":"8","author":"Kuehn","year":"2024","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0585","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40291-021-00563-1","article-title":"Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis","volume":"26","author":"Melosky","year":"2022","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.addr.2025.115736_bb0590","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1158\/1078-0432.CCR-17-0890","article-title":"for the German Glioma Network, Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors","volume":"23","author":"Felsberg","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0595","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","article-title":"Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma","volume":"20","author":"Snuderl","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.addr.2025.115736_bb0600","article-title":"Intracranial Outcomes of De Novo Brain Metastases Treated With Osimertinib Alone in Patients With Newly Diagnosed EGFR-Mutant NSCLC","volume":"4","author":"Imber","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0605","article-title":"High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience","volume":"3","author":"Piper-Vallillo","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0610","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","article-title":"AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer","volume":"4","author":"Cross","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115736_bb0615","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13046-019-1235-7","article-title":"The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma","volume":"38","author":"Liu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0620","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ijrobp.2010.01.070","article-title":"Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo\/North Central Cancer Treatment Group Study N0074","volume":"80","author":"Uhm","year":"2011","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0625","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034","volume":"27","author":"van den Bent","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0630","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.bjc.6603669","article-title":"Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)","volume":"96","author":"Franceschi","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb0635","article-title":"A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma","volume":"7","author":"Ellingson","year":"2025","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.addr.2025.115736_bb0645","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2023-189856","article-title":"Functional Precision Medicine Vs Genomics Vs Clinical Experience: Feasibility Results from the Multicentric, Prospective, Randomized Controlled Exalt-2 Trial","volume":"142","author":"Kazianka","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.addr.2025.115736_bb0650","article-title":"Cancer stem cell assay-guided chemotherapy improves survival of patients with recurrent glioblastoma in a randomized trial","volume":"4","author":"Ranjan","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0655","year":"2021","journal-title":"FDA"},{"key":"10.1016\/j.addr.2025.115736_bb0665","author":"Center for Devices and Radiological Health, Laboratory Developed Tests, FDA"},{"key":"10.1016\/j.addr.2025.115736_bb0670","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.molmed.2024.10.015","article-title":"Functional precision medicine: the future of cancer care","volume":"31","author":"Acanda de la Rocha","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0675","article-title":"FDA\u2019s ISTAND Pilot Program accepts a submission of first organ-on-a-chip technology designed to predict human drug-induced liver injury (DILI)","author":"Center for Drug Evaluation and Research","year":"2024","journal-title":"FDA"},{"key":"10.1016\/j.addr.2025.115736_bb0680","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0685","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jim.2015.04.020","article-title":"Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials \u2014 Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm","volume":"424","author":"Vessillier","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.addr.2025.115736_bb0690","doi-asserted-by":"crossref","first-page":"19731","DOI":"10.1038\/s41598-025-04862-z","article-title":"Machine learning and multi-omics analysis reveal key regulators of proneural\u2013mesenchymal transition in glioblastoma","volume":"15","author":"Xu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0695","doi-asserted-by":"crossref","unstructured":"X. Pan, B. Burgman, E. Wu, J.H. Huang, N. Sahni, S. Stephen Yi, i-Modern: Integrated multi-omics network model identifies potential therapeutic targets in glioma by deep learning with interpretability, Comput. Struct. Biotechnol. J. 20 (2022) 3511\u20133521. doi:https:\/\/doi.org\/10.1016\/j.csbj.2022.06.058.","DOI":"10.1016\/j.csbj.2022.06.058"},{"key":"10.1016\/j.addr.2025.115736_bb0700","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1021\/acs.jcim.3c00347","article-title":"A Hybrid Structure-Based Machine Learning Approach for Predicting Kinase Inhibition by Small Molecules","volume":"63","author":"Liu","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.addr.2025.115736_bb0705","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1038\/s41591-024-03224-y","article-title":"High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity","volume":"30","author":"Lee","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0710","doi-asserted-by":"crossref","first-page":"15844","DOI":"10.1038\/s41598-024-66897-y","article-title":"Predicting blood\u2013brain barrier permeability of molecules with a large language model and machine learning","volume":"14","author":"Huang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0715","doi-asserted-by":"crossref","first-page":"16310","DOI":"10.1038\/s41598-019-52213-6","article-title":"Proof-of-Concept Study of Drug Brain Permeability Between in Vivo Human Brain and an in Vitro iPSCs-Human Blood-Brain Barrier Model","volume":"9","author":"Roux","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0720","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1021\/acs.jcim.4c00504","article-title":"CNSMolGen: A Bidirectional Recurrent Neural Network-Based Generative Model for De Novo Central Nervous System Drug Design","volume":"64","author":"Gou","year":"2024","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.addr.2025.115736_bb0725","doi-asserted-by":"crossref","unstructured":"J. Zhang, J. Cunningham, J. Brown, R. Gatenby, Evolution-based mathematical models significantly prolong response to abiraterone in metastatic castrate-resistant prostate cancer and identify strategies to further improve outcomes, eLife 11 (2022) e76284. doi:https:\/\/doi.org\/10.7554\/eLife.76284.","DOI":"10.7554\/eLife.76284"},{"key":"10.1016\/j.addr.2025.115736_bb0730","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.3390\/jcm10102169","article-title":"In Silico Mathematical Modelling for Glioblastoma: A Critical Review and a Patient-Specific Case","volume":"10","author":"Falco","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0735","doi-asserted-by":"crossref","first-page":"1563829","DOI":"10.3389\/fimmu.2025.1563829","article-title":"CAR-T cell therapy for glioblastoma: insight from mathematical modeling","volume":"16","author":"Szafra\u0144ska-\u0141\u0119czycka","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.addr.2025.115736_bb0740","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s11071-024-10258-x","article-title":"Dual CAR-T cell therapy for glioblastoma: strategies to cure tumour diseases based on a mathematical model","volume":"113","author":"Bodnar","year":"2025","journal-title":"Nonlinear Dyn."},{"key":"10.1016\/j.addr.2025.115736_bb0745","article-title":"Medical digital twins: enabling precision medicine and medical artificial intelligence","volume":"0","author":"Sad\u00e9e","year":"2025","journal-title":"Lancet Digit. Health"},{"key":"10.1016\/j.addr.2025.115736_bb0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0314083","article-title":"DigiLoCS: A leap forward in predictive organ-on-chip simulations","volume":"20","author":"Aravindakshan","year":"2025","journal-title":"PLOS ONE"},{"key":"10.1016\/j.addr.2025.115736_bb0755","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41746-024-01188-4","article-title":"From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling","volume":"7","author":"Wang","year":"2024","journal-title":"NPJ Digit. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0760","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2023.100895","article-title":"Why haven\u2019t we solved intracranial pediatric ependymoma? Current questions and barriers to treatment advances","volume":"39","author":"Hwang","year":"2023","journal-title":"Neoplasia"},{"key":"10.1016\/j.addr.2025.115736_bb0765","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000530868","article-title":"Recent Advancements in Ependymoma: Challenges and Therapeutic Opportunities","volume":"58","author":"Bertrand","year":"2023","journal-title":"Pediatr. Neurosurg."},{"key":"10.1016\/j.addr.2025.115736_bb0770","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307818","article-title":"Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol","volume":"19","author":"Toh","year":"2024","journal-title":"PLOS ONE"},{"key":"10.1016\/j.addr.2025.115736_bb0775","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13046-023-02853-4","article-title":"Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer","volume":"42","author":"Cartry","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0780","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1038\/s41467-023-38832-8","article-title":"Drug screening at single-organoid resolution via bioprinting and interferometry","volume":"14","author":"Tebon","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115736_bb0785","doi-asserted-by":"crossref","first-page":"6572","DOI":"10.3390\/ijms23126572","article-title":"Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma","volume":"23","author":"Ratliff","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115736_bb0790","author":"Azzam"},{"key":"10.1016\/j.addr.2025.115736_bb0795","doi-asserted-by":"crossref","unstructured":"M. Shatara, M.R. Paul, J.R. Long-Boyle, A. Meyer, S. Raber, L. Yeh-Nayre, A. Jalkanen, L.B. Kilburn, R.J. Packer, J.D. Elster, A.T. Reddy, C. Koschmann, A. Kraya, A.C. Resnick, M. Prados, C. Kline, S. Mueller, R.J. Wechsler-Reya, J.B. Rubin, Trls-04. Early insights from PNOC027: Personalized treatment approaches based on real-time drug screening and genomic testing in pediatric and adolescent patients with recurrent medulloblastoma, Neuro-Oncol. 26 (2024) 0. doi:https:\/\/doi.org\/10.1093\/neuonc\/noae064.157.","DOI":"10.1093\/neuonc\/noae064.157"},{"key":"10.1016\/j.addr.2025.115736_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109788","article-title":"Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models","volume":"37","author":"Stockslager","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0805","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","article-title":"Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers","volume":"30","author":"Acanda De La Rocha","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0810","author":"Ourotech, Inc."},{"key":"10.1016\/j.addr.2025.115736_bb0815","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-019-0253-6","article-title":"Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment","volume":"8","author":"Skaga","year":"2019","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0820","doi-asserted-by":"crossref","first-page":"954","DOI":"10.12688\/f1000research.135809.2","article-title":"Ex-vivo drug screening of surgically resected glioma stem cells to replace murine avatars and provide personalise cancer therapy for glioblastoma patients","volume":"12","author":"Gagg","year":"2024","journal-title":"F1000Research"},{"key":"10.1016\/j.addr.2025.115736_bb0825","doi-asserted-by":"crossref","DOI":"10.1063\/1.5120555","article-title":"Brain-on-a-chip: A history of development and future perspective","volume":"13","author":"Bang","year":"2019","journal-title":"Biomicrofluidics"},{"key":"10.1016\/j.addr.2025.115736_bb0830","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1038\/s41467-022-30384-7","article-title":"A role for microfluidic systems in precision medicine","volume":"13","author":"Ayuso","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115736_bb0835","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-21-0799","article-title":"A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture","volume":"82","author":"Chakrabarty","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0840","doi-asserted-by":"crossref","first-page":"1904321","DOI":"10.1002\/smll.201904321","article-title":"Microfluidics as an Enabling Technology for Personalized Cancer Therapy","volume":"16","author":"Mathur","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.addr.2025.115736_bb0845","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/pharmaceutics16050574","article-title":"Evaluation of Drug Blood-Brain-Barrier Permeability Using a Microfluidic Chip","volume":"16","author":"Yang","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115736_bb0850","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40478-025-01928-x","article-title":"Personalising glioblastoma medicine: explant organoid applications, challenges and future perspectives","volume":"13","author":"Skarne","year":"2025","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.addr.2025.115736_bb0855","article-title":"Potential of ex vivo organotypic slice cultures in neuro-oncology","volume":"noae195","author":"Steindl","year":"2024","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0860","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.3390\/cancers15164104","article-title":"Patient-Derived Ex Vivo Cultures and Endpoint Assays with Surrogate Biomarkers in Functional Testing for Prediction of Therapeutic Response","volume":"15","author":"Tsukamoto","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2025.115736_bb0865","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1158\/1538-7445.AM2023-4563","article-title":"Abstract 4563: Measuring immunotherapy responses ex vivo using novel 3D culture platform: E-slice","volume":"83","author":"Gallup","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0870","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114552","article-title":"A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis","volume":"14","author":"Zhu","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0875","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1158\/1538-7445.AM2022-694","article-title":"Abstract 694: E-slice: A novel 3D culture platform for precision medicine","volume":"82","author":"Gopalan","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb0880","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0885","article-title":"A living ex vivo platform for functional, personalized brain cancer diagnosis","volume":"4","author":"Mann","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.addr.2025.115736_bb0890","first-page":"1","article-title":"Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine","volume":"9","author":"Mann","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0895","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.omto.2022.06.004","article-title":"Spatiotemporal analysis of induced neural stem cell therapy to overcome advanced glioblastoma recurrence","volume":"26","author":"Satterlee","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.addr.2025.115736_bb0900","first-page":"OF1","article-title":"Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma","author":"Kaanoglu","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2025.115736_bb0905","series-title":"A microengineered Brain-Chip to model neuroinflammation in humans, iScience 25","author":"Pediaditakis","year":"2022"},{"key":"10.1016\/j.addr.2025.115736_bb0910","doi-asserted-by":"crossref","first-page":"2303180","DOI":"10.1002\/adhm.202303180","article-title":"Microphysiological Blood-Brain Barrier Systems for Disease Modeling and Drug Development","volume":"13","author":"Mulay","year":"2024","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.addr.2025.115736_bb0915","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.tibtech.2022.04.003","article-title":"A hitchhiker\u2019s guide to cancer models","volume":"40","author":"Budhwani","year":"2022","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2025.115736_bb0920","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12935-025-03692-3","article-title":"Targeting stromal cells in tumor microenvironment as a novel treatment strategy for glioma","volume":"25","author":"Geng","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.addr.2025.115736_bb0925","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41419-023-06110-6","article-title":"Stromal cells in the tumor microenvironment: accomplices of tumor progression?","volume":"14","author":"Zhao","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.addr.2025.115736_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101860","article-title":"A review of protocols for brain organoids and applications for disease modeling","volume":"4","author":"Mayhew","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100524","article-title":"A robust protocol for the generation of human midbrain organoids","volume":"2","author":"Zagare","year":"2021","journal-title":"STAR Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb0940","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.celrep.2019.02.063","article-title":"Modeling Patient-Derived Glioblastoma with Cerebral Organoids","volume":"26","author":"Linkous","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2025.115736_bb0945","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103212","article-title":"Protocol for the generation of cultured cortical brain organoid slices","volume":"5","author":"Petersilie","year":"2024","journal-title":"STAR Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101365","article-title":"Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models with 4D Bioprinted Arrays","volume":"23","author":"Chadwick","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.addr.2025.115736_bb0955","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2025.103895","article-title":"Protocol for the biofabrication of immunocompetent tumor-on-chip models from patient solid tumors for assessment of anticancer therapies","volume":"6","author":"Nurmik","year":"2025","journal-title":"STAR Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103300","article-title":"Protocol to generate a microfluidic vessels-on-chip platform using human pluripotent stem cell-derived endothelial cells","volume":"5","author":"Remmert","year":"2024","journal-title":"STAR Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb0965","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.actbio.2019.04.053","article-title":"AKR1B10 (Aldo-keto reductase family 1 B10) promotes brain metastasis of lung cancer cells in a multi-organ microfluidic chip model","volume":"91","author":"Liu","year":"2019","journal-title":"Acta Biomater."},{"key":"10.1016\/j.addr.2025.115736_bb0970","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102174","article-title":"Generation of 3D ex vivo mouse- and patient-derived glioma explant slice model for integration of confocal time-lapse imaging and spatial analysis","volume":"4","author":"Comba","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103401","article-title":"Protocol using ex vivo mouse brain slice culture mimicking in vivo conditions to study tumor growth and cell motility of glioblastoma cells","volume":"5","author":"Neises","year":"2024","journal-title":"STAR Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb0980","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201900305","article-title":"Human organotypic brain slice culture: a novel framework for environmental research in neuro-oncology","volume":"2","author":"Ravi","year":"2019","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.addr.2025.115736_bb0985","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41586-023-05905-z","article-title":"Computational approaches streamlining drug discovery","volume":"616","author":"Sadybekov","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.addr.2025.115736_bb0990","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1123492","article-title":"In vivo loss of tumorigenicity in a patient-derived orthotopic xenograft mouse model of ependymoma","volume":"13","author":"Whitehouse","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb0995","article-title":"Patient-derived models of brain metastases recapitulate human disseminated disease","volume":"3","author":"Faria","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.addr.2025.115736_bb1000","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-019-1086-5","article-title":"Patient-derived xenografts of different grade gliomas retain the heterogeneous histological and genetic features of human gliomas","volume":"20","author":"Zeng","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.addr.2025.115736_bb1005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-019-0024-5","article-title":"Applications of machine learning in drug discovery and development","volume":"18","author":"Vamathevan","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.addr.2025.115736_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.media.2024.103423","article-title":"Personalized predictions of Glioblastoma infiltration: Mathematical models, Physics-Informed Neural Networks and multimodal scans","volume":"101","author":"Zhang","year":"2025","journal-title":"Med. Image Anal."},{"key":"10.1016\/j.addr.2025.115736_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbs.2024.109207","article-title":"Mathematical modeling of brain metastases growth and response to therapies: A review","volume":"373","author":"Oca\u00f1a-Tienda","year":"2024","journal-title":"Math. Biosci."},{"key":"10.1016\/j.addr.2025.115736_bb1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106830","article-title":"Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation","volume":"194","author":"Zhou","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.addr.2025.115736_bb1025","doi-asserted-by":"crossref","first-page":"8229","DOI":"10.1021\/acsomega.1c03618","article-title":"Understanding the Effect of Functionalization on Loading Capacity and Release of Drug from Mesoporous Silica Nanoparticles: A Computationally Driven Study","volume":"7","author":"Narayan","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2025.115736_bb1030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human organs-on-chips for disease modelling, drug development and personalized medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.addr.2025.115736_bb1035","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41416-023-02402-y","article-title":"Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers","volume":"129","author":"Ntafoulis","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb1040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/neuonc\/noad047","article-title":"The development of a rapid patient-derived xenograft model to predict chemotherapeutic drug sensitivity\/resistance in malignant glial tumors","volume":"25","author":"Charbonneau","year":"2023","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1045","doi-asserted-by":"crossref","first-page":"14282","DOI":"10.1038\/s41598-025-98565-0","article-title":"Leveraging TME features and multi-omics data with an advanced deep learning framework for improved Cancer survival prediction","volume":"15","author":"Fan","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb1050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41540-024-00419-4","article-title":"Spatial computational modelling illuminates the role of the tumour microenvironment for treating glioblastoma with immunotherapies","volume":"10","author":"Mongeon","year":"2024","journal-title":"Npj Syst. Biol. Appl."},{"key":"10.1016\/j.addr.2025.115736_bb1055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1124\/jpet.122.001571","article-title":"Agent-Based Modelling Reveals the Role of the Tumor Microenvironment on the Short-Term Success of Combination Temozolomide\/Immune Checkpoint Blockade to Treat Glioblastoma","volume":"387","author":"Surendran","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.addr.2025.115736_bb1060","doi-asserted-by":"crossref","first-page":"9246","DOI":"10.1038\/s41598-021-88687-6","article-title":"Calcium carbonate nanoparticles stimulate cancer cell reprogramming to suppress tumor growth and invasion in an organ-on-a-chip system","volume":"11","author":"Lam","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb1065","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s42003-023-05531-5","article-title":"A fully 3D-printed versatile tumor-on-a-chip allows multi-drug screening and correlation with clinical outcomes for personalized medicine","volume":"6","author":"Steinberg","year":"2023","journal-title":"Commun. Biol."},{"key":"10.1016\/j.addr.2025.115736_bb1070","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1039\/D4ME00056K","article-title":"Innovative strategies for the quantitative modeling of blood\u2013brain barrier (BBB) permeability: harnessing the power of machine learning-based q-RASAR approach","volume":"9","author":"Kumar","year":"2024","journal-title":"Mol. Syst. Des. Eng."},{"key":"10.1016\/j.addr.2025.115736_bb1075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/ph18020217","article-title":"Computational Modeling of Pharmaceuticals with an Emphasis on Crossing the Blood\u2013Brain Barrier","volume":"18","author":"Alves","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.addr.2025.115736_bb1080","doi-asserted-by":"crossref","unstructured":"F.M.G. Cornelissen, G. Markert, G. Deutsch, M. Antonara, N. Faaij, I. Bartelink, D. Noske, W.P. Vandertop, A. Bender, B.A. Westerman, Explaining Blood\u2013Brain Barrier Permeability of Small Molecules by Integrated Analysis of Different Transport Mechanisms, J. Med. Chem. 66 (2023) 7253\u20137267. doi:https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01824.","DOI":"10.1021\/acs.jmedchem.2c01824"},{"key":"10.1016\/j.addr.2025.115736_bb1085","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2025.1535112","article-title":"Developing a predictive model for blood-brain-barrier permeability to explore relevance of in vitro neurotoxicity data for in vivo risk assessment","volume":"7","author":"Illa","year":"2025","journal-title":"Front. Toxicol."},{"key":"10.1016\/j.addr.2025.115736_bb1090","doi-asserted-by":"crossref","first-page":"25387","DOI":"10.1038\/s41598-025-10744-1","article-title":"Identification and evaluation of pyrimidine based CDK6 inhibitors against glioblastoma using integrated computational approaches","volume":"15","author":"Manzoor","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb1095","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1038\/s41598-024-53684-y","article-title":"The Temozolomide\u2013Doxorubicin paradox in Glioblastoma in vitro\u2013in silico preclinical drug-screening","volume":"14","author":"Oraiopoulou","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb1100","doi-asserted-by":"crossref","unstructured":"G.G. da Silva, D.P. Sacomani, B.G. de Carvalho, M.A. Porcionatto, A. Gobbi, R.S. Lima, L.G. de la Torre, Microfluidic Systems to Mimic the Blood\u2013Brain Barrier: from Market to Engineering Challenges and Perspectives, ACS Biomater. Sci. Eng. 11 (n.d.) 3789\u20133815. doi:https:\/\/doi.org\/10.1021\/acsbiomaterials.4c02221.","DOI":"10.1021\/acsbiomaterials.4c02221"},{"key":"10.1016\/j.addr.2025.115736_bb1105","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.tibtech.2024.11.021","article-title":"Vascularized human brain organoids: current possibilities and prospects","volume":"43","author":"Kistemaker","year":"2025","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.addr.2025.115736_bb1110","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.stem.2024.04.019","article-title":"Modeling blood-brain barrier formation and cerebral cavernous malformations in human PSC-derived organoids","volume":"31","author":"Dao","year":"2024","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.addr.2025.115736_bb1115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12987-023-00482-9","article-title":"A tissue-engineered model of the blood-tumor barrier during metastatic breast cancer","volume":"20","author":"Linville","year":"2023","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.addr.2025.115736_bb1120","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/bit.26045","article-title":"Microfluidic blood\u2013brain barrier model provides in vivo-like barrier properties for drug permeability screening","volume":"114","author":"Wang","year":"2017","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.addr.2025.115736_bb1125","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s43246-024-00721-y","article-title":"Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma","volume":"6","author":"Mokarram","year":"2025","journal-title":"Commun. Mater."},{"key":"10.1016\/j.addr.2025.115736_bb1130","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.3390\/cells10082036","article-title":"Human Blood Vessel Organoids Penetrate Human Cerebral Organoids and Form a Vessel-Like System","volume":"10","author":"Ahn","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.addr.2025.115736_bb1135","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1007\/s00259-022-05997-1","article-title":"In vivo methods for imaging blood\u2013brain barrier function and dysfunction","volume":"50","author":"Harris","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.addr.2025.115736_bb1140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12987-024-00617-6","article-title":"In vivo brain delivery of BBB-enabled iduronate 2-sulfatase in rats","volume":"22","author":"Costain","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.addr.2025.115736_bb1145","doi-asserted-by":"crossref","DOI":"10.1016\/j.greeac.2024.100096","article-title":"Ethical principles and scientific advancements: In vitro, in silico, and non-vertebrate animal approaches for a green ecotoxicology","volume":"8","author":"Pastorino","year":"2024","journal-title":"Green Anal. Chem."},{"key":"10.1016\/j.addr.2025.115736_bb1150","article-title":"Ethics of Artificial Intelligence in Medicine","volume":"17","author":"Park","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.addr.2025.115736_bb1155","first-page":"685","article-title":"Artificial intelligence ethics in precision oncology: balancing advancements in technology with patient privacy and autonomy","volume":"4","author":"Far","year":"2023","journal-title":"Explor. Target. Anti-Tumor Ther."},{"key":"10.1016\/j.addr.2025.115736_bb1160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/biotech10030012","article-title":"Ethical Challenges in Organoid Use","volume":"10","author":"Mollaki","year":"2021","journal-title":"BioTech"},{"key":"10.1016\/j.addr.2025.115736_bb1165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2024.151470","article-title":"Beyond consciousness: Ethical, legal, and social issues in human brain organoid research and application","volume":"104","author":"Kataoka","year":"2025","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.addr.2025.115736_bb1170","first-page":"E255","article-title":"Ethical considerations regarding animal experimentation","volume":"63","author":"Kiani","year":"2022","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.addr.2025.115736_bb1175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/cancers17020198","article-title":"Advancing Cancer Drug Delivery with Nanoparticles: Challenges and Prospects in Mathematical Modeling for In Vivo and In Vitro Systems","volume":"17","author":"Munyayi","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2025.115736_bb1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103043","article-title":"Applying artificial intelligence and computational modeling to nanomedicine","volume":"85","author":"Hamilton","year":"2024","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.addr.2025.115736_bb1185","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1021\/acsnano.9b08142","article-title":"Meta-Analysis of Nanoparticle Delivery to Tumors Using a Physiologically Based Pharmacokinetic Modeling and Simulation Approach","volume":"14","author":"Cheng","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115736_bb1190","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.csbj.2020.02.014","article-title":"A mathematical model to predict nanomedicine pharmacokinetics and tumor delivery","volume":"18","author":"Dogra","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.addr.2025.115736_bb1195","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s10544-019-0380-2","article-title":"Mathematical modeling in cancer nanomedicine: a review","volume":"21","author":"Dogra","year":"2019","journal-title":"Biomed. Microdevices"},{"key":"10.1016\/j.addr.2025.115736_bb1200","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1452298","article-title":"Hybrid-integrated devices for mimicking malignant brain tumors (\u201ctumor-on-a-chip\u201d) for in vitro development of targeted drug delivery and personalized therapy approaches","volume":"11","author":"Zimina","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.addr.2025.115736_bb1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115646","article-title":"From cell-SELEX to tissue-SELEX for targeted drug delivery and aptamer nanomedicine","volume":"224","author":"Wong","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115736_bb1210","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1021\/acs.analchem.1c01445","article-title":"Identification of a New DNA Aptamer by Tissue-SELEX for Cancer Recognition and Imaging","volume":"93","author":"Li","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.addr.2025.115736_bb1215","doi-asserted-by":"crossref","unstructured":"J.-W. Choi, K. Kim, K. Mukhambetiyar, N.K. Lee, J. Sabat\u00e9 del R\u00edo, J. Joo, C.G. Park, T. Kwon, T.-E. Park, Organ-on-a-Chip Approach for Accelerating Blood\u2013Brain Barrier Nanoshuttle Discovery, ACS Nano 18 (2024) 14388\u201314402. doi:https:\/\/doi.org\/10.1021\/acsnano.4c00994.","DOI":"10.1021\/acsnano.4c00994"},{"key":"10.1016\/j.addr.2025.115736_bb1220","doi-asserted-by":"crossref","first-page":"2400502","DOI":"10.1002\/adma.202400502","article-title":"Dual-Targeted Novel Temozolomide Nanocapsules Encapsulating siPKM2 Inhibit Aerobic Glycolysis to Sensitize Glioblastoma to Chemotherapy","volume":"36","author":"Zhang","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.addr.2025.115736_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122964","article-title":"Self-emulsifying drug delivery systems (SEDDS): In vivo-proof of concept for oral delivery of insulin glargine","volume":"639","author":"Claus","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115736_bb1230","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1021\/acs.nanolett.0c04753","article-title":"A Biomimetic Drug Delivery System by Integrating Grapefruit Extracellular Vesicles and Doxorubicin-Loaded Heparin-Based Nanoparticles for Glioma Therapy","volume":"21","author":"Niu","year":"2021","journal-title":"Nano Lett."},{"key":"10.1016\/j.addr.2025.115736_bb1235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41698-024-00583-0","article-title":"Overcoming limitations in current measures of drug response may enable AI-driven precision oncology","volume":"8","author":"Ovchinnikova","year":"2024","journal-title":"Npj Precis. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1240","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1086097","article-title":"Deep learning methods for drug response prediction in cancer: Predominant and emerging trends","volume":"10","author":"Partin","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.addr.2025.115736_bb1245","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/bib\/bbz171","article-title":"Deep learning for drug response prediction in cancer","volume":"22","author":"Baptista","year":"2021","journal-title":"Brief. Bioinform."},{"key":"10.1016\/j.addr.2025.115736_bb1250","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100755","article-title":"Cancer Stem Cell Chemotherapeutics Assay for Prospective Treatment of Recurrent Glioblastoma and Progressive Anaplastic Glioma: A Single-Institution Case Series","volume":"13","author":"Ranjan","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1255","first-page":"153","article-title":"PDX models for functional precision oncology and discovery science","volume":"25","author":"Blanchard","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb1260","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1038\/s41467-023-38552-z","article-title":"Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma","volume":"14","author":"Potter","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.addr.2025.115736_bb1265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.neo.2020.11.005","article-title":"Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine","volume":"23","author":"Rivera","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.addr.2025.115736_bb1270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12987-025-00650-z","article-title":"Proteome profile differences among human, monkey, and mouse brain microvessels and cultured brain microvascular endothelial cells","volume":"22","author":"Kumabe","year":"2025","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.addr.2025.115736_bb1275","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/cpt.3505","article-title":"Mechanistic Modeling of Spatial Heterogeneity of Drug Penetration and Exposure in the Human Central Nervous System and Brain Tumors","volume":"117","author":"Li","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.addr.2025.115736_bb1280","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114816","article-title":"An overview of in vitro 3D models of the blood-brain barrier as a tool to predict the in vivo permeability of nanomedicines","volume":"196","author":"P\u00e9rez-L\u00f3pez","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115736_bb1285","doi-asserted-by":"crossref","first-page":"16150","DOI":"10.1038\/s41598-023-43214-7","article-title":"Validation and characterization of a novel blood\u2013brain barrier platform for investigating traumatic brain injury","volume":"13","author":"Bolden","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb1290","doi-asserted-by":"crossref","first-page":"2205752","DOI":"10.1002\/advs.202205752","article-title":"3D In Vitro Blood-Brain-Barrier Model for Investigating Barrier Insults","volume":"10","author":"Wei","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2025.115736_bb1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101087","article-title":"Bioengineered microfluidic blood-brain barrier models in oncology research","volume":"14","author":"Augustine","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1300","doi-asserted-by":"crossref","unstructured":"X.-Y. Sun, X.-C. Ju, Y. Li, P.-M. Zeng, J. Wu, Y.-Y. Zhou, L.-B. Shen, J. Dong, Y.-J. Chen, Z.-G. Luo, Generation of vascularized brain organoids to study neurovascular interactions, eLife 11 (2022) e76707. doi:https:\/\/doi.org\/10.7554\/eLife.76707.","DOI":"10.7554\/eLife.76707"},{"key":"10.1016\/j.addr.2025.115736_bb1305","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1093\/neuonc\/noae001","article-title":"Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma","volume":"26","author":"Odia","year":"2024","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1310","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biomaterials.2018.07.014","article-title":"3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes","volume":"180","author":"Campisi","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2025.115736_bb1315","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: Structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2025.115736_bb1320","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41596-021-00635-w","article-title":"Engineered human blood\u2013brain barrier microfluidic model for vascular permeability analyses","volume":"17","author":"Hajal","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb1325","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/neuonc\/noad031","article-title":"Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908","volume":"25","author":"Dunkel","year":"2023","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1330","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1158\/1078-0432.CCR-15-0124","article-title":"Failures in Phase III: Causes and Consequences, Clin. Cancer Res","volume":"21","author":"Seruga","year":"2015","journal-title":"Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb1335","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2159-8290.CD-23-0559","article-title":"Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium","volume":"14","author":"Das","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.addr.2025.115736_bb1340","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.23.00493","article-title":"Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization","volume":"41","author":"Rahman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1345","doi-asserted-by":"crossref","DOI":"10.1080\/14737167.2025.2526065","article-title":"Proposed method for economic evaluation based on basket trials: a case study of pembrolizumab","author":"Nosrati","year":"2025","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"10.1016\/j.addr.2025.115736_bb1350","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.addr.2025.115736_bb1355","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12874-024-02272-9","article-title":"Adaptive designs in clinical trials: a systematic review-part I","volume":"24","author":"Ben-Eltriki","year":"2024","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.addr.2025.115736_bb1375","doi-asserted-by":"crossref","unstructured":"L. Marcus, L.A. Fashoyin-Aje, M. Donoghue, M. Yuan, L. Rodriguez, P.S. Gallagher, R. Philip, S. Ghosh, M.R. Theoret, J.A. Beaver, R. Pazdur, S.J. Lemery, FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden\u2013High Solid Tumors, Clin. Cancer Res. 27 (2021) 4685\u20134689. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0327.","DOI":"10.1158\/1078-0432.CCR-21-0327"},{"key":"10.1016\/j.addr.2025.115736_bb1380","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.3390\/cancers14112699","article-title":"In Silico Investigations of Multi-Drug Adaptive Therapy Protocols","volume":"14","author":"Thomas","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2025.115736_bb1385","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/bio.2023.0140","article-title":"Updating International Society for Biological and Environmental Repositories Best Practices, Fifth Edition: A New Process for Relevance in an Evolving Landscape","volume":"21","author":"Snapes","year":"2023","journal-title":"Biopreservation Biobanking"},{"key":"10.1016\/j.addr.2025.115736_bb1390","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A Patient-Derived Glioblastoma Organoid Model and Biobank Recapitulates Inter- and Intra-tumoral Heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.addr.2025.115736_bb1395","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","article-title":"Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing","volume":"15","author":"Jacob","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.addr.2025.115736_bb1400","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/bio.2020.0050","article-title":"Optimization of Viable Glioblastoma Cryopreservation for Establishment of Primary Tumor Cell Cultures","volume":"19","author":"Valyi-Nagy","year":"2021","journal-title":"Biopreservation Biobanking"},{"key":"10.1016\/j.addr.2025.115736_bb1405","doi-asserted-by":"crossref","first-page":"4960","DOI":"10.1158\/1538-7445.AM2024-4960","article-title":"Abstract 4960: PIONEER initiative: Providing patient access to functional precision medicine","volume":"84","author":"Dixon","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115736_bb1410","unstructured":"Personalized targeted glioblastoma therapies by ex vivo drug screening, CBmed (2025). https:\/\/www.cbmed.at\/project\/attract\/ (accessed July 16, 2025)."},{"key":"10.1016\/j.addr.2025.115736_bb1415","article-title":"ATTRACT study group, Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT)","volume":"7","author":"Berghoff","year":"2025","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.addr.2025.115736_bb1425","unstructured":"A. Berghoff, Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening: Advanced Brain Tumor TheRApy Clinical Trial (ATTRACT), clinicaltrials.gov, 2024. https:\/\/clinicaltrials.gov\/study\/NCT06512311 (accessed July 16, 2025)."},{"key":"10.1016\/j.addr.2025.115736_bb1430","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41416-018-0359-4","article-title":"Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas","volume":"120","author":"Brodin","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb1435","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tranon.2017.01.008","article-title":"Analysis of Chemopredictive Assay for Targeting Cancer Stem Cells in Glioblastoma Patients","volume":"10","author":"Howard","year":"2017","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2025.115736_bb1440","article-title":"Prospective prediction of clinical drug response in high-grade gliomas using an ex vivo 3D cell culture assay","volume":"3","author":"Shuford","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"10.1016\/j.addr.2025.115736_bb1445","doi-asserted-by":"crossref","first-page":"19474","DOI":"10.1038\/s41598-024-68801-0","article-title":"Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma","volume":"14","author":"Ledford","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115736_bb1450","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114608","article-title":"In vitro and invivo drug screens of tumor cells identify novel therapies for high-risk child cancer","volume":"14","author":"Lau","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.addr.2025.115736_bb1460","unstructured":"K.H. Kim, Patient-derived Organoids As Predictive Models for Drug Response Testing and Repurporsing in Glioblastoma Therapy, clinicaltrials.gov, 2025. https:\/\/clinicaltrials.gov\/study\/NCT06782984 (accessed July 19, 2025)."},{"key":"10.1016\/j.addr.2025.115736_bb1470","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1158\/1535-7163.MCT-22-0714","article-title":"The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Cancer Research for 35 Years","volume":"22","author":"McCall","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.addr.2025.115736_bb1475","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011279","article-title":"Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic","volume":"13","author":"Eguren-Santamaria","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.addr.2025.115736_bb1480","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1038\/s41467-024-49873-y","article-title":"Delayed tumor-draining lymph node irradiation preserves the efficacy of combined radiotherapy and immune checkpoint blockade in models of metastatic disease","volume":"15","author":"Telarovic","year":"2024","journal-title":"Nat. Commun."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25002212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:51:58Z","timestamp":1781167918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25002212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":246,"alternative-id":["S0169409X25002212"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115736","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Informing development of brain cancer therapies within \"preclinical trials\" using ex vivo patient tumors","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115736"}}